Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Ltd (ADVENZYMES) last traded at ₹299, a market capitalisation of ₹3,348 crore, on a P/E of 21.2. Over the past 52 weeks the stock has ranged between ₹252 and ₹420. Advanced Enzyme Technologies Ltd last reported results for the quarter ended Jun 2026, with sales of ₹190 crore and net profit of ₹39 crore. Figures are as of 25 Aug 2026 and are not real time.
Advanced Enzyme Technologies Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Advanced Enzyme Technologies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹190 cr, up 2.2% from ₹186 cr a year earlier. Net profit was ₹39 cr, down 2.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| Expenses | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 |
| Operating profit | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 51 |
| OPM % | 29% | 33% | 27% | 30% | 33% | 29% | 31% | 27% |
| Other income | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 13 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 |
| Tax % | 21% | 27% | 38% | 26% | 25% | 26% | 24% | 28% |
| Net profit | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 |
| EPS (₹) | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 | 3.31 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Advanced Enzyme Technologies Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 502 | 529 | 541 | 624 | 637 | 746 | 750 |
| Operating profit | 232 | 203 | 158 | 206 | 196 | 230 | 224 |
| OPM % | 46% | 38% | 29% | 33% | 31% | 31% | 30% |
| Net profit | 151 | 124 | 104 | 137 | 134 | 174 | 172 |
| EPS (₹) | 13.09 | 10.70 | 9.45 | 11.92 | 11.72 | 15.07 | 14.82 |
TTM is the trailing twelve months to the most recent quarter.
Advanced Enzyme Technologies Ltd growth and returns
- 10 Years
- 10%
- 5 Years
- 8%
- 3 Years
- 11%
- TTM
- 12%
- 10 Years
- 7%
- 5 Years
- 1%
- 3 Years
- 12%
- TTM
- 15%
- 10 Years
- 1%
- 5 Years
- -4%
- 3 Years
- -2%
- 1 Year
- -2%
- 10 Years
- 13%
- 5 Years
- 10%
- 3 Years
- 10%
- Last Year
- 10%
Advanced Enzyme Technologies Ltd shareholding pattern
Promoters held 43.25% at Jun 2026, broadly unchanged since Jun 2025. FIIs 26.70% and DIIs 4.77%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.95% | 42.92% | 43.08% | 43.08% | 43.08% | 43.04% | 43.26% | 43.25% |
| FIIs | 12.63% | 12.57% | 11.90% | 23.45% | 25.41% | 25.85% | 25.50% | 26.70% |
| DIIs | 8.02% | 8.17% | 8.19% | 8.45% | 6.41% | 5.51% | 5.41% | 4.77% |
| Public | 36.40% | 36.31% | 36.82% | 25.00% | 25.09% | 25.62% | 25.85% | 25.28% |
| No. of shareholders | 66,758 | 67,351 | 65,322 | 67,589 | 69,637 | 68,051 | 66,193 | 63,599 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Advanced Enzyme Technologies Ltd corporate filings
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 25, 2026. Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 72,807 equity shares…
Read the full analysis - Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 24, 2026. Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 40,876 equity shares…
Read the full analysis - Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 21, 2026. Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the daily progress of its ongoing open…
Read the full analysis - Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 20, 2026 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the acquisition of 88,274 equity…
Read the full analysis - Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 19, 2026 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 67,748 equity shares…
Read the full analysis - Transcript of Conference Call held on August 12, 2026 for the Unaudited Financial Results for the Quarter ended June 30, 2026Company Updatemedium impact
Cruxal's analysis: Advanced Enzyme Technologies reported a soft Q1 FY27 with revenue of INR 189.8 crore…
Read the full analysis - Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 18, 2026 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 94,686 equity shares…
Read the full analysis - Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 17, 2026 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 65,252 equity shares…
Read the full analysis - Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on August 14, 2026 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has reported the daily execution of its ongoing…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeCompany Updatelow impact
Cruxal's analysis: Advanced Enzyme Technologies Ltd. has formally uploaded the audio recording of its…
Read the full analysis - Bord Resolution for the BuybackCompany Updatehigh impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has approved a buyback of equity shares via the open…
Read the full analysis - Public Announcement - BuyBack of the Equity SharesCompany Updatehigh impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has announced a buyback of equity shares from the…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has released its unaudited consolidated financial…
Read the full analysis - Press Release titled Quaterly Earnings Release dated August 08, 2026Company Updatemedium impact
Cruxal's analysis: Advanced Enzyme Technologies Limited reported Q1 FY27 consolidated revenue of 189.8…
Read the full analysis - Earnings Presentation for the Quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Advanced Enzyme Technologies Limited reported Q1 FY27 consolidated revenue of 189.8…
Read the full analysis - 1) Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 2)Approved the Buyback of fully paid-up equity shares 3)Approved ....Board Meetinghigh impact
Cruxal's analysis: Advanced Enzyme Technologies reported Q1 FY27 consolidated revenue of 189.79 crore and…
Read the full analysis - Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we would like to inform that the ....Company Updatelow impact
Cruxal's analysis: Advanced Enzyme Technologies Ltd has announced it will host a conference call for…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Advanced Enzyme Technologies Ltd
Cruxal reads every Advanced Enzyme Technologies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.